

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3978967

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
NOVARTIS AG	07/01/2016
NOVARTIS PHARMA AG	07/01/2016
SPEEDEL HOLDING AG	07/01/2016

RECEIVING PARTY DATA

Name:	NODEN PHARMA DAC
Street Address:	5 BELSIZE DRIVE
City:	TORONTO, ONTARIO
State/Country:	CANADA
Postal Code:	M4S 1L3

PROPERTY NUMBERS Total: 20

Property Type	Number
Patent Number:	5559111
Patent Number:	8168616
Patent Number:	9023893
Patent Number:	9023894
Patent Number:	8618174
Patent Number:	8183295
Patent Number:	8617595
Patent Number:	8007824
Patent Number:	7772405
Patent Number:	8198465
Patent Number:	8618172
Patent Number:	8613949
Patent Number:	6730798
Application Number:	10515817
Patent Number:	7009078
Patent Number:	7132569
Patent Number:	6777574
Patent Number:	6800769

PATENT

Property Type	Number
Patent Number:	7153675
Patent Number:	8338620

CORRESPONDENCE DATA

Fax Number: (214)200-0853
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.
Email: whitney.remily@haynesboone.com
Correspondent Name: HAYNES AND BOONE, LLP
Address Line 1: 2323 VICTORY AVENUE, SUITE 700
Address Line 4: DALLAS, TEXAS 75219

ATTORNEY DOCKET NUMBER:	54658.2
NAME OF SUBMITTER:	WHITNEY REMILY
SIGNATURE:	/Whitney Remily/
DATE SIGNED:	07/26/2016

Total Attachments: 25
source=Assignment#page1.tif
source=Assignment#page2.tif
source=Assignment#page3.tif
source=Assignment#page4.tif
source=Assignment#page5.tif
source=Assignment#page6.tif
source=Assignment#page7.tif
source=Assignment#page8.tif
source=Assignment#page9.tif
source=Assignment#page10.tif
source=Assignment#page11.tif
source=Assignment#page12.tif
source=Assignment#page13.tif
source=Assignment#page14.tif
source=Assignment#page15.tif
source=Assignment#page16.tif
source=Assignment#page17.tif
source=Assignment#page18.tif
source=Assignment#page19.tif
source=Assignment#page20.tif
source=Assignment#page21.tif
source=Assignment#page22.tif
source=Assignment#page23.tif
source=Assignment#page24.tif
source=Assignment#page25.tif

PATENT ASSIGNMENT AGREEMENT

This PATENT ASSIGNMENT AGREEMENT (the "Assignment") dated as of July 1, 2016 (the "Effective Date"), is entered into by and between Novartis AG, a company organized under the laws of Switzerland and located at Forum 1, Novartis Campus, 4056 Basel, Switzerland ("NAG"), Novartis Pharma AG, a company organized under the laws of Switzerland and located at Lichtstrasse 35, 4056 Basel, Switzerland ("NPAG"), Speedel Holding AG, a company organized under the laws of Switzerland and located at Forum 1, Novartis Campus, 4056 Basel ("Speedel") (NAG, NPAG and Speedel collectively, referred to collectively as the "Assignors" and individually as an "Assignor") and Noden Pharma DAC, a company organized under the laws of Ireland ("Purchaser"). The Assignors and Purchaser are referred to herein individually as "Party" or collectively as "Parties."

PRELIMINARY STATEMENTS

WHEREAS, the Assignors and Purchaser have entered into that certain Asset Purchase Agreement, dated May 24, 2016 (hereinafter the "APA"), in connection with which the Assignors have agreed to sell, and Purchaser has agreed to purchase, the Transferred Intellectual Property, including the patents and patent applications set forth on Schedule A hereto (the "Transferred Patents");

WHEREAS, pursuant to the APA, each Assignor desires to assign to Purchaser, and Purchaser desires to receive, the Transferred Patents.

NOW, THEREFORE, pursuant to the APA and in consideration of the foregoing and the mutual covenants and agreements contained in this Assignment, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

1. Definitions. Unless otherwise defined herein, terms used in this Assignment, including its preamble and recitals, have the meanings provided or provided by reference in the APA.

2. Assignment. Pursuant to and subject to the terms and conditions of the APA, each Assignor hereby assigns and transfers to Purchaser, its successors and assigns, and Purchaser hereby accepts, all of each Assignor's right, title and interest in and to the following: (a) the Transferred Patents including the inventions claimed therein and any reissues, reexamination, divisions, continuations, continuations-in-part, extensions and counterparts of such Transferred Patents already granted and which may be granted therefrom, together with (i) the right to prosecute, maintain and defend the Transferred Patents before any public or private agency, office or registrar; (ii) the right, if any, to claim priority based on the filing dates of any of the Transferred Patents under the Paris Convention for the Protection of Industrial Property of March 20, 1883, the Patent Cooperation Treaty of June 19, 1970, the European Patent Convention of October 5, 1973 and all other treaties of like purposes; and (iii) any and all provisional and other priority patent applications related to the Transferred Patents, whether or not specifically recited therein, required to claim such priority; and (b) all rights to causes of action (whether known or unknown or whether currently pending, filed or otherwise) under, or on account of, any of the Transferred Patents, including the right to sue for past, current and

future infringement or other violation of the Transferred Patents and obtain in connection therewith (i) damages; (ii) injunctive relief; and (iii) any other remedies of any kind; with all of the foregoing rights to be held and enjoyed by Purchaser for its own use and enjoyment and the use and enjoyment of its successors, assigns and other legal representatives to the end of the term or terms for which the Transferred Patents are granted, reissued, renewed, extended or revived as fully and entirely as the same would have been held and enjoyed by each Assignor if this assignment had not been made.

3. Recordation. Each Assignor hereby authorizes the relevant authorities, entities or agencies in any applicable foreign countries or multinational authorities to record Purchaser as the Purchaser and owner of the Transferred Patents and to deliver to Purchaser, and to Purchaser's attorneys, agents, successors or assigns, all official documents and communications as may be warranted by this Assignment.


4. Miscellaneous. Clause 1.2 of the APA and each Clause of Article 18 of the APA is incorporated herein by reference, *mutatis mutandis*.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, The Assignors and Purchaser have caused this Assignment to be executed on the date first written above by their respective duly authorized officers.


ASSIGNORS


By: Novartis AG

Signature: 
Name: Thierry Droz-Georget
Title: Head of Partnering
General Medicine & Mature Products


Signature: 
Name: Martin Berchtold
Title: Legal Counsel


By: Novartis Pharma AG

Signature: 
Name: Gregor von Arn
Title: Head Legal Established Medicines Franchise

Signature: 
Name: Walid Kattouha
Title: Global Business Franchise Head
Established Medicines
4002 BASEL, SWITZERLAND

By: Speedel Holding AG


Signature: 
Name: J.-M. Séquier
Title: Legal Counsel

Signature: 
Name: J.-M. Séquier
Title: Business Development & Licensing
Forum 2.5.01.24
Tel: 45825 Fax 67179

[SIGNATURE PAGE TO PATENT ASSIGNMENT AGREEMENT]

PURCHASER

By: Noden Pharma DAC

Signature: 

Name: Elie Farah

Title: Director

[SIGNATURE PAGE TO PATENT ASSIGNMENT AGREEMENT]

PAT019919	PAT019919-4N-NP	DELTA-AMINO-GAMMA-HYDROXY- OMEGA-ARYL-ALKANAMIDES, RERIN INHIBITORS	Malaysia	P195000816	30 Mar 1995	95-119161-A	30 Apr 2005	Novartis AG	Switzerland (NP) - 18 Grant Apr 1994 - 1169/94	30-Apr-17	30-Apr-20
PAT019919	PAT019919-NL-SFC	DELTA-AMINO-GAMMA-HYDROXY- OMEGA-ARYL-ALKANAMIDES, RERIN INHIBITORS	Netherlands	3002396	27 Sep 2007	3002396	05 Dec 2007	Novartis AG	Switzerland (NP) - 18 Grant Apr 1994 - 1169/94	30-Apr-17	6-Apr-20
PAT019919	PAT019919-NO-SFC	DELTA-AMINO-GAMMA-HYDROXY- OMEGA-ARYL-ALKANAMIDES, RERIN INHIBITORS	Norway	2007/011	31 Oct 2007		25 May 2011	Novartis AG	Switzerland (NP) - 18 Grant Apr 1994 - 1169/94	30-Apr-17	12-Apr-20
PAT019919	PAT019919-PH-NP	DELTA-AMINO-GAMMA-HYDROXY- OMEGA-ARYL-ALKANAMIDES, RERIN	Philippines	1-1995-50333	17 Apr 1995	1-1995-50333	05 Jul 1999	Novartis AG	Switzerland (NP) - 18 Grant Apr 1994 - 1169/94	7-Apr-17	5-Jul-16
PAT019919	PAT019919-PT-SFC	DELTA-AMINO-GAMMA-HYDROXY- OMEGA-ARYL-ALKANAMIDES, RERIN	Portugal	268	30 Oct 2007		28 Mar 2008	Novartis AG	Switzerland (NP) - 18 Grant Apr 1994 - 1169/94	7-Apr-17	7-Apr-20
PAT019919	PAT019919-SE-SFC	DELTA-AMINO-GAMMA-HYDROXY- OMEGA-ARYL-ALKANAMIDES, RERIN INHIBITORS	Sweden	0795052-5	01 Nov 2007	0795052-5	18 Mar 2008	Novartis AG	Switzerland (NP) - 18 Grant Apr 1994 - 1169/94	30-Apr-17	7-Apr-20
PAT019919	PAT019919-TW-EXT	DELTA-AMINO-GAMMA-HYDROXY- OMEGA-ARYL-ALKANAMIDES, RERIN INHIBITORS	Taiwan	084103732	30 Oct 2008	PH-118380	05 Jan 2012	Novartis AG	Switzerland (NP) - 18 Grant Apr 1994 - 1169/94	14-Apr-20	14-Apr-20
PAT019919	PAT019919-TW-NP	DELTA-AMINO-GAMMA-HYDROXY- OMEGA-ARYL-ALKANAMIDES, RERIN INHIBITORS	Taiwan	84103732	15 Apr 1995	95-119380	04 Jan 2001	Novartis AG	Switzerland (NP) - 18 Grant Apr 1994 - 1169/94	20-Aug-15	14-Apr-20
PAT019919	PAT019919-US-NP	DELTA-AMINO-GAMMA-HYDROXY- OMEGA-ARYL-ALKANAMIDES, RERIN INHIBITORS	United States of America	08/416242	04 Apr 1995	9559311	24 Sep 1996	Novartis Corporation	Switzerland (NP) - 18 Grant Apr 1994 - 1169/94	21-Jul-18	21-Jul-18
PAT01652	PAT01652-AT-EPT	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	Austria	01996377.6	15 Nov 2001	1341533	15 Feb 2006	Novartis Pharma AG	United Kingdom (NP) - Grant 17 Nov 2000 - 0028151.9	30-Nov-16	15-Nov-21
PAT01652	PAT01652-AU-EXT	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	Australia	201223680	04 Feb 2010			Novartis AG	United Kingdom (NP) - Annulment paid until end of life	7-Apr-25	7-Apr-25
PAT01652	PAT01652-AU-PCT	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	Australia	202223680	15 Nov 2001	200223680	22 Jul 2005	Novartis AG	United Kingdom (NP) - Annulment paid until end of life	7-Apr-25	7-Apr-25
PAT01652	PAT01652-BE-EPT	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	Belgium	01996377.6	15 Nov 2001	1341533	15 Feb 2006	Novartis AG	United Kingdom (NP) - Grant 17 Nov 2000 - 0028151.9	30-Nov-16	15-Nov-21
PAT01652	PAT01652-BR-PCT	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	Brazil	P10115411-7	15 Nov 2001			Novartis AG	United Kingdom (NP) - Publication of Application	15-Nov-16	15-Nov-21
PAT01652	PAT01652-BR-PCTD	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	Brazil	P10117379-0	26 Sep 2011			Novartis AG	United Kingdom (NP) - Appeal Filed (PT)	15-Nov-16	15-Nov-21
PAT01652	PAT01652-BR- PCTD02	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	Brazil	122016004255-0	26 Feb 2016			Novartis AG	United Kingdom (NP) - Filed 17 Nov 2000 - 0028151.9	15-Nov-16	15-Nov-21
PAT01652	PAT01652-CH-EPT	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	Switzerland	01996377.6	15 Nov 2001	1341533	15 Feb 2006	Novartis AG	United Kingdom (NP) - Grant 17 Nov 2000 - 0028151.9	30-Nov-16	15-Nov-21
PAT01652	PAT01652-CO-PCT	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	Colombia	03034889	15 Nov 2001	518	23 Mar 2010	Novartis AG	United Kingdom (NP) - Grant 17 Nov 2000 - 0028151.9	30-Nov-16	15-Nov-21
PAT01652	PAT01652-CY-EPT	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	Cyprus (Republic)	01996377.6	15 Nov 2001	1341533	15 Feb 2006	Novartis AG	United Kingdom (NP) - Grant 17 Nov 2000 - 0028151.9	14-Nov-16	15-Nov-21
PAT01652	PAT01652-CZ-PCT	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	Czech Republic	PV2003-1341	15 Nov 2001	299749	01 Oct 2008	Novartis AG	United Kingdom (NP) - Grant 17 Nov 2000 - 0028151.9	15-Nov-16	15-Nov-21
PAT01652	PAT01652-CZ-PCTD	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	Czech Republic	PV2007-665	21 Sep 2007			Novartis AG	United Kingdom (NP) - Filed 17 Nov 2000 - 0028151.9	15-Nov-16	15-Nov-21
PAT01652	PAT01652-DE-EPT	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	Germany	01996377.6	15 Nov 2001	60117295.7	15 Feb 2006	Novartis AG	United Kingdom (NP) - Grant 17 Nov 2000 - 0028151.9	30-Nov-16	15-Nov-21
PAT01652	PAT01652-DK-EPT	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	Denmark	01996377.6	15 Nov 2001	1341533	15 Feb 2006	Novartis AG	United Kingdom (NP) - Grant 17 Nov 2000 - 0028151.9	30-Nov-16	15-Nov-21
PAT01652	PAT01652-EF- EFD02	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	European Procedure	08502401.1	08 Feb 2008	EP0105963	10 Jul 2013	Novartis AG	United Kingdom (NP) - Opposition filed 17 Nov 2000 - 0028151.9	30-Nov-16	15-Nov-21
PAT01652	PAT01652-EF- EPD04	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	European Procedure	10179109.3	24 Sep 2010			Novartis AG	United Kingdom (NP) - Publication of Application	30-Nov-16	15-Nov-21
PAT01652	PAT01652-ES-EPT	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	Spain	01996377.6	15 Nov 2001	1341533	15 Feb 2006	Novartis AG	United Kingdom (NP) - Grant 17 Nov 2000 - 0028151.9	30-Nov-16	15-Nov-21
PAT01652	PAT01652-FI-EPT	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases	Finland	01996377.6	15 Nov 2001	1341533	15 Feb 2006	Novartis AG	United Kingdom (NP) - Grant 17 Nov 2000 - 0028151.9	30-Nov-16	15-Nov-21

PAT031652	PAT031652-FR-EPT	Synergistic combinations comprising a France renin inhibitor for cardiovascular diseases	01996377.6	15 Nov 2001 1341533	15 Feb 2006 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	30 Nov-16	15-Nov-21
PAT031652	PAT031652-GB-EPT	Synergistic combinations comprising a United Kingdom renin inhibitor for cardiovascular diseases	01996377.6	15 Nov 2001 1341533	15 Feb 2006 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	30 Nov-16	15-Nov-21
PAT031652	PAT031652-GR-EPT	Synergistic combinations comprising a Greece renin inhibitor for cardiovascular diseases	01996377.6	15 Nov 2001 1341533	15 Feb 2006 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	30 Nov-16	15-Nov-21
PAT031652	PAT031652-HK-FPO2	Synergistic combinations comprising a Hong Kong renin inhibitor for cardiovascular diseases	04102924.7	11 Feb 2004 1059212	08 Dec 2006 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	15-Nov-16	15-Nov-21
PAT031652	PAT031652-HK-FD04	Synergistic combinations comprising a Hong Kong renin inhibitor for cardiovascular diseases	11109508.3	08 Sep 2011	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	15-Nov-17	15-Nov-21
PAT031652	PAT031652-HK-FPR	Synergistic combinations comprising a Hong Kong renin inhibitor for cardiovascular diseases	06106355.0	11 Feb 2004 1089366	30 Apr 2009 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	15-Nov-16	15-Nov-21
PAT031652	PAT031652-HU-PCT	Synergistic combinations comprising a Hungary renin inhibitor for cardiovascular diseases	P0301841	15 Nov 2001	Novartis AG	United Kingdom (UK) - Publication of Application 17 Nov 2000 - 0028151.9	15-Nov-16	15-Nov-21
PAT031652	PAT031652-HU-PCTD	Synergistic combinations comprising a Hungary renin inhibitor for cardiovascular diseases	P1400409	28 Aug 2014	Novartis AG	United Kingdom (UK) - Publication of Application 17 Nov 2000 - 0028151.9	15-Nov-16	15-Nov-21
PAT031652	PAT031652-ID-PCT	Synergistic combinations comprising an Indonesia renin inhibitor for cardiovascular diseases	W00200700853	15 Nov 2001 ID00223658	24 Nov 2008 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	30-Nov-15	15-Nov-21
PAT031652	PAT031652-ID-PCTD	Synergistic combinations comprising an Indonesia renin inhibitor for cardiovascular diseases	W00200801657	23 May 2008 ID00035510	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	14-Feb-17	15-Nov-21	
PAT031652	PAT031652-IE-EPT	Synergistic combinations comprising an Ireland renin inhibitor for cardiovascular diseases	01996377.6	15 Nov 2001 1341533	15 Feb 2006 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	30-Nov-16	15-Nov-21
PAT031652	PAT031652-IL-PCT	Pharmaceutical Compositions Comprising a Combination of a Renin Inhibitor and at Least One Therapeutic Agent and Uses Thereof for the Manufacture of Medicaments for the Prevention of, Delay of or Pharmaceutical Compositions Comprising a Combination of a Renin Inhibitor and at Least One Therapeutic Agent and Uses Thereof for the Manufacture of Medicaments for the Prevention of, Delay of or	355707	15 Nov 2001 135707	16 Apr 2013 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	15-Nov-19	15-Nov-21
PAT031652	PAT031652-IL-PCTD	Pharmaceutical Compositions Comprising a Combination of a Renin Inhibitor and at Least One Therapeutic Agent and Uses Thereof for the Manufacture of Medicaments for the Prevention of, Delay of or	212075	31 Mar 2011 212075	30 Nov 2013 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	15-Nov-19	15-Nov-21
PAT031652	PAT031652-IT-EPT	Synergistic combinations comprising an Italy renin inhibitor for cardiovascular diseases	01996377.6	15 Nov 2001 1341533	15 Feb 2006 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	30-Nov-16	15-Nov-21
PAT031652	PAT031652-JP-PCT002	Synergistic combinations comprising a Japan renin inhibitor for cardiovascular diseases	2013-148269	17 Jul 2013	Novartis AG	United Kingdom (UK) - Publication of Application 17 Nov 2000 - 0028151.9	15-Nov-21	15-Nov-21
PAT031652	PAT031652-KR-PCT005	Synergistic combinations comprising a South Korea / Republic of Korea renin inhibitor for cardiovascular diseases	2011-7012347	30 May 2011 1254365	19 Apr 2013 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	15-Nov-17	15-Nov-21
PAT031652	PAT031652-LU-EPT	Synergistic combinations comprising a Luxembourg renin inhibitor for cardiovascular diseases	01996377.6	15 Nov 2001 1341533	15 Feb 2006 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	30-Nov-16	15-Nov-21
PAT031652	PAT031652-MC-EPT	Synergistic combinations comprising a Monaco renin inhibitor for cardiovascular diseases	01996377.6	15 Nov 2001 1341533	15 Feb 2006 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	30-Nov-16	15-Nov-21
PAT031652	PAT031652-MX-PCTD	Synergistic combinations comprising a Mexico renin inhibitor for cardiovascular diseases	PA/4/2006/007966	12 Jul 2006 258575	15 Feb 2006 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	30-Nov-16	15-Nov-21
PAT031652	PAT031652-NL-EPT	Synergistic combinations comprising a Netherlands renin inhibitor for cardiovascular diseases	01996377.6	15 Nov 2001 1341533	15 Feb 2006 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	30-Nov-16	15-Nov-21
PAT031652	PAT031652-NO-PCT	Synergistic combinations comprising a Norway renin inhibitor for cardiovascular diseases	20032223	15 Nov 2001 1344002	13 Aug 2008 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	15-Nov-19	15-Nov-21
PAT031652	PAT031652-NO-SPC	Synergistic combinations comprising a Norway renin inhibitor for cardiovascular diseases	2013019	17 Dec 2013 334902	15 Feb 2006 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	30-Nov-16	15-Nov-21
PAT031652	PAT031652-NZ-PCT	Synergistic combinations comprising a New Zealand renin inhibitor for cardiovascular diseases	525795	15 Nov 2001 525795	19 Feb 2015 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	30-Nov-16	15-Nov-21
PAT031652	PAT031652-NZ-PCT005	Synergistic combinations comprising a New Zealand renin inhibitor for cardiovascular diseases	550857	30 Oct 2006 550857	30 Jul 2008 Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 - 0028151.9	15-Nov-16	15-Nov-21

PAT031652	PAT031652-PH-PCT	Synergistic combinations comprising a Philippines renin inhibitor for cardiovascular diseases	1-2003-500370	15 Nov 2001 1-2003-500370	23 Jul 2007	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	23-May-17	15-Nov-21
PAT031652	PAT031652-PH-PCTD	Synergistic combinations comprising a Philippines renin inhibitor for cardiovascular diseases	1-2006-501767	17 Sep 2006 1-2006-501767	10 Feb 2012	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	23-May-17	15-Nov-21
PAT031652	PAT031652-PL-PCT	Synergistic combinations comprising a Poland renin inhibitor for cardiovascular diseases	P-361404	15 Nov 2001		Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -		15-Nov-21
PAT031652	PAT031652-PT-EPT	Synergistic combinations comprising a Portugal renin inhibitor for cardiovascular diseases	01996377.6	15 Nov 2001 1341533	15 Feb 2006	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	15-Nov-16	15-Nov-21
PAT031652	PAT031652-RO-EPT	Synergistic combinations comprising a Romania renin inhibitor for cardiovascular diseases	01996377.6	15 Nov 2001 EP1341533	15 Feb 2006	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	15-Nov-16	15-Nov-21
PAT031652	PAT031652-RU-EXT	Synergistic combinations comprising a Russian Federation renin inhibitor for cardiovascular diseases	2346703	26 Jan 2011 2346703	25 May 2011	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	15-Nov-16	30-Jul-25
PAT031652	PAT031652-RU-PCT	Synergistic combinations comprising a Russian Federation renin inhibitor for cardiovascular diseases	2003116896	15 Nov 2001 2310443	05 Mar 2007	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	15-Nov-16	15-Nov-21
PAT031652	PAT031652-RU-PCTD	Synergistic combinations comprising a Russian Federation renin inhibitor for cardiovascular diseases	2006132668	12 Sep 2006 2346703	17 Jun 2009	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	15-Nov-16	30-Jul-25
PAT031652	PAT031652-SE-EPT	Synergistic combinations comprising a Sweden renin inhibitor for cardiovascular diseases	01996377.6	15 Nov 2001 1341533	15 Feb 2006	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	30-Nov-16	15-Nov-21
PAT031652	PAT031652-SG-PCT	Synergistic combinations comprising a Singapore renin inhibitor for cardiovascular diseases	200302315-7	15 Nov 2001 96424	31 Aug 2005	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	15-Nov-16	15-Nov-21
PAT031652	PAT031652-SG-PCTD	Synergistic combinations comprising a Singapore renin inhibitor for cardiovascular diseases	200504685-9	28 Jul 2005 135969	26 Feb 2010	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	15-Nov-16	15-Nov-21
PAT031652	PAT031652-SI-EPT	Synergistic combinations comprising a Slovenia renin inhibitor for cardiovascular diseases	01996377.6	15 Nov 2001 EP1341533	15 Feb 2006	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	15-Nov-16	15-Nov-21
PAT031652	PAT031652-SK-PCT	Synergistic combinations comprising a Slovakia renin inhibitor for cardiovascular diseases	PP594-2003	15 Nov 2001 287881	13 Dec 2011	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	15-Nov-16	15-Nov-21
PAT031652	PAT031652-SK-PCTD	Synergistic combinations comprising a Slovakia renin inhibitor for cardiovascular diseases	PP595-11	18 Feb 2011		Novartis AG	United Kingdom (UK) - Filed 17 Nov 2000 -	15-Nov-21	15-Nov-21
PAT031652	PAT031652-TU-EPT	Synergistic combinations comprising a Turkey renin inhibitor for cardiovascular diseases	01996377.6	15 Nov 2001 TR200602103	15 Feb 2006	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	15-Nov-16	15-Nov-21
PAT031652	PAT031652-US-PCT	Synergistic combinations comprising a United States of America renin inhibitor for cardiovascular diseases	107416039	15 Nov 2001 8168916	01 May 2012	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	1-Nov-19	3-Jul-26
PAT031652	PAT031652-US-PCTD	Synergistic combinations comprising a United States of America renin inhibitor for cardiovascular diseases	13/235559	19 Sep 2011 8023893	05 May 2015	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	5-Nov-18	15-Nov-21
PAT031652	PAT031652-US-PCTD02	Synergistic combinations comprising a United States of America renin inhibitor for cardiovascular diseases	13/235756	19 Sep 2011 9073994	05 May 2015	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	5-Nov-18	15-Nov-21
PAT031652	PAT031652-US-PCTD03	Synergistic combinations comprising a United States of America renin inhibitor for cardiovascular diseases	13/235767	19 Sep 2011 9618174	31 Dec 2013	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	30-Jun-17	15-Nov-21
PAT031652	PAT031652-VN-PCT	Synergistic combinations comprising a Vietnam renin inhibitor for cardiovascular diseases	1-2003-00542	15 Nov 2001 5368	20 Dec 2005	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	20-Dec-16	15-Nov-21
PAT031652	PAT031652-ZA-PCT	Synergistic combinations comprising a South Africa renin inhibitor for cardiovascular diseases	2003/2497	15 Nov 2001 2003/2497	30 Jun 2004	Novartis AG	United Kingdom (UK) - Grant 17 Nov 2000 -	15-Nov-16	15-Nov-21
PAT032494	PAT032494-US-CMT	Pharmaceutical Composition comprising a Renin Inhibitor, a Diuretic, a Calcium Channel Blocker, and a Galenic Formulations of Organic Compounds	12/188604	08 Aug 2008 8103295	22 May 2012	Novartis AG	United States of America (US) - 17 Mar 2004 60/531546 Publication of United States of America (US) - 17 Mar 2004	22-Nov-19	16-May-23
PAT033668	PAT033668-AR-NP	Galenic Formulations of Organic Compounds	PO50100999	15 Mar 2005		Novartis AG	United States of America (US) - 17 Mar 2004 60/531878 Publication of United States of America (US) - 17 Mar 2004	16-Mar-17	15-Mar-25
PAT033668	PAT033668-AU-PCT	Galenic Formulations of Organic Compounds	2005224010	16 Mar 2005 2005224010	11 Jun 2009	Novartis AG	United States of America (US) - 17 Mar 2004 60/533876 Publication of United States of America (US) - 17 Mar 2004	16-Mar-17	16-Mar-25
PAT033688	PAT033688-AU-PCTD	Galenic Formulations of Organic Compounds	20092020669	26 May 2009 20092020669	31 May 2017	Novartis AG	United States of America (US) - 17 Mar 2004 60/533876 Publication of United States of America (US) - 17 Mar 2004	16-Mar-17	16-Mar-25

PAT033689	PAT033688-BK-PCT	Galenic Formulations of Organic Compounds	Brazil	910508833.0	16 Mar 2005	Novartis AG	United States of America (PSP) - 17 Mar 2004	16-Mar-17	16-Mar-25
PAT033688	PAT033688-CI-NP	Galenic Formulations of Organic Compounds	Chile	572/2005	16 Mar 2005	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004		
PAT033688	PAT033688-CN-PCT	Galenic Formulations of Organic Compounds	China	303580006233.1	16 Mar 2005 200580006233.1	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	16-Mar-17	16-Mar-25
PAT033688	PAT033688-CO-PCT	Galenic Formulations of Organic Compounds	Colombia	05092594	16 Mar 2005	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004		16-Mar-25
PAT033688	PAT033688-CO-PCTD	Galenic Formulations of Organic Compounds	Colombia	06020594A	30 Jun 2011	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004		16-Mar-25
PAT033688	PAT033688-EZ-PCT	Galenic Formulations of Organic Compounds	Algeria	060495	16 Mar 2005 4728	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	16-Mar-17	16-Mar-25
PAT033688	PAT033688-EG-PCT	Galenic Formulations of Organic Compounds	Egypt	854/2006	16 Mar 2005	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004		16-Mar-25
PAT033688	PAT033688-EI-ETO	COMMERCIAL SOLID ORAL DOSAGE FORMS COMPRISING ALISKIREN (SPP100)	European Procedure	10177494.1	17 Sep 2010	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	15-Mar-17	16-Mar-25
PAT033688	PAT033688-EP-ETD	COMMERCIAL SOLID ORAL DOSAGE FORMS COMPRISING ALISKIREN (SPP100)	European Procedure	10177494.1	17 Sep 2010	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	31-Mar-17	16-Mar-25
PAT033688	PAT033688-HK-FTD	Galenic Formulations of Organic Compounds	Hong Kong	11106003.9	14 Jun 2011	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004		16-Mar-25
PAT033688	PAT033688-ID-PCT	Galenic Formulations of Organic Compounds	Indonesia	W0030602464	16 Mar 2005 150202382	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	26-May-17	16-Mar-25
PAT033688	PAT033688-ID-PCTD	Galenic Formulations of Organic Compounds	Indonesia	W00201101154	30 Mar 2011 150333109	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	22-Feb-17	16-Mar-25
PAT033688	PAT033688-IL-PCT	Galenic Formulations of Organic Compounds	Israel	177424	16 Mar 2005 177424	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	16-Mar-17	16-Mar-25
PAT033688	PAT033688-IN-PCT	Galenic Formulations of Organic Compounds	India	3372/CHEM/2006	16 Mar 2005 254949	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	16-Mar-17	16-Mar-25
PAT033688	PAT033688-JP-PCTD	Galenic Formulations of Organic Compounds	Japan	2012-129230	06 Jun 2012	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	16-Mar-17	16-Mar-25
PAT033688	PAT033688-KR-PCT	Galenic Formulations of Organic Compounds	South Korea / Republic of Korea	2006-7018968	16 Mar 2005 1274855	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	7-Jun-17	16-Mar-25
PAT033688	PAT033688-KR-PCTD	Galenic Formulations of Organic Compounds	South Korea / Republic of Korea	2013-7005111	27 Feb 2013 1353726	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	14-Jun-17	16-Mar-25
PAT033688	PAT033688-MA-PCT	Galenic Formulations of Organic Compounds	Morocco	PA29347	16 Mar 2005 28490	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	16-Mar-17	16-Mar-25
PAT033688	PAT033688-MX-PCTD	Galenic Formulations of Organic Compounds	Mexico	MX/A/12/004612	19 Apr 2012	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004		16-Mar-25
PAT033688	PAT033688-MY-DIV	Galenic Formulations of Organic Compounds	Malaysia	P120090494	13 Feb 2009 MY-148773-A	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	31-May-17	16-Mar-25

PAT033688	PAT033688-NP-NP	Galenic Formulations of Organic Compounds	Malaysia	PZ20051084	15 Mar 2005 NY 344477-A	30 Sep 2011 Novartis AG	United States of America (PSP) - 17 Mar 2004	Grant	30 Sep 16	15-Mar-25
PAT033688	PAT033688-NO-PCT	Galenic Formulations of Organic Compounds	Norway	30064670	16 Mar 2005	Novartis AG	United States of America (PSP) - 17 Mar 2004	Local filing	31-Mar-17	16-Mar-25
PAT033688	PAT033688-NZ-PCT	Galenic Formulations of Organic Compounds	New Zealand	548823	16 Mar 2005 548823	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	Grant	16 Mar-17	16-Mar-25
PAT033688	PAT033688-PE-DIV03	Galenic Formulations of Organic Compounds	Pecu	001265-2014/DIN	13 Aug 2014	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	Opposition filed	31-Mar-17	15-Mar-25
PAT033688	PAT033688-PE-NP	Galenic Formulations of Organic Compounds	Pecu	000286/2005-OIN	15 Mar 2005	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	Publication of Application	31-Mar-17	15-Mar-25
PAT033688	PAT033688-PH-PCT	Galenic Formulations of Organic Compounds	Philippines	1-2006-501491	16 Mar 2005 1-2006-501491	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	Publication of grant	9-Sep-16	16-Mar-25
PAT033688	PAT033688-PK-DIV	Galenic Formulations of Organic Compounds	Pakistan	294/08	17 Mar 2008 139778	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	Grant	17-Mar-17	17-Mar-24
PAT033688	PAT033688-PK-NP	Galenic Formulations of Organic Compounds	Pakistan	243/2005	16 Mar 2005 139763	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	Grant	17-Mar-17	17-Mar-24
PAT033688	PAT033688-RU-PCT	Galenic Formulations of Organic Compounds	Russian Federation	2005136090	15 Mar 2005 2384328	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	Grant	16-Mar-17	16-Mar-25
PAT033688	PAT033688-RU-PCT	Galenic Formulations of Organic Compounds	Russian Federation	2009139446	20 Oct 2009 7439061	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	Grant	16-Mar-17	16-Mar-25
PAT033688	PAT033688-RU-PCT	Galenic Formulations of Organic Compounds	Russian Federation	2011135405	25 Aug 2011 7490210	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	Grant	16-Mar-17	16-Mar-25
PAT033688	PAT033688-SG-PCT	Galenic Formulations of Organic Compounds	Singapore	200904140.1	17 Jun 2009 133830	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	Grant	16-Mar-17	16-Mar-25
PAT033688	PAT033688-TH-NP	Galenic Formulations of Organic Compounds	Thailand	0501000981	07 Mar 2005	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	Publication of Application	7-Mar-25	7-Mar-25
PAT033688	PAT033688-TN-PCT	Galenic Formulations of Organic Compounds	Tunisia	5806209	16 Mar 2005	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	Local filing	31-Mar-17	16-Mar-25
PAT033688	PAT033688-TW-NP	Galenic Formulations of Organic Compounds	Taiwan	084108055	16 Mar 2005 7406656	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	Grant	31-Aug-16	16-Mar-25
PAT033688	PAT033688-US-PCT	Galenic Formulations of Organic Compounds	United States of America	10/590398	16 Mar 2005 8617595	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	Grant	30-Jun-17	2-Jul-26
PAT033688	PAT033688-VE-NP	Galenic Formulations of Organic Compounds	Venezuela	505-05	16 Mar 2005	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	Publication of Application	16-Mar-17	16-Mar-25
PAT033688	PAT033688-ZA-PCT	Galenic Formulations of Organic Compounds	South Africa	2006/06220	16 Mar 2005 2006/06220	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	Grant	16-Mar-17	16-Mar-25
PAT033688	PAT033688-US-CIP	Galenic Formulations of Organic Compounds	United States of America	11/153738	15 Jun 2005 8007624	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	Grant	26-Feb-16	29-Oct-27
PAT033688	PAT033688-AR-NP	3-alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Anti-HIV Inhibitors	Argentina	PA60104497	13 Oct 2005	Novartis AG	60/553878 United States of America (PSP) - 17 Mar 2004	Publication of Application	13-Oct-26	13-Oct-26
PAT033688	PAT033688-AT-EPT	Organic Compounds	Austria	06828821.6	16 Oct 2006 671048643	Novartis AG	60/553878 United States of America (PSP) - 17 Oct 2005 - 0521083.6	Grant	31-Oct-16	16-Oct-26

PATD34561	PATD34561-AU-PCT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Australia	2006303489	16 Oct 2006	2006303489	21 Jul 2011	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-BE-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Belgium	06629821.6	16 Oct 2006	EP1948643	05 Jun 2013	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-BG-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Bulgaria	06629821.6	16 Oct 2006	EP1948643	05 Jun 2013	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-BR-PCT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Brazil	PI0617492.2	16 Oct 2006			Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-CH-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Switzerland	06629821.6	16 Oct 2006	EP1948643	05 Jun 2013	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-CL-NP	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Chile	27803706	16 Oct 2006	505598	09 Sep 2014	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-CN-PCT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	China	200680003597.9	16 Oct 2006	200680003597.9	13 Feb 2013	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-CN-PCTD	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	China	Z01210566662.6	24 Dec 2012			Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-CO-PCT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Colombia	06629821.6	16 Oct 2006	4304	30 Aug 2013	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-CY-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Cyprus (Republic)	06629821.6	16 Oct 2006	EP1948643	05 Jun 2013	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-CZ-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Czech Republic	06629821.6	16 Oct 2006	EP1948643	05 Jun 2013	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-DE-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Germany	06629821.6	16 Oct 2006	602006036705.8	05 Jun 2013	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-DK-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Denmark	06629821.6	16 Oct 2006	EP1948643	05 Jun 2013	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-DZ-PCT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Algeria	060302	16 Oct 2006	5866	15 Sep 2010	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-EE-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Estonia	06629821.6	16 Oct 2006	EP1948643	05 Jun 2013	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-EG-PCT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Egypt	PCT/615/2008	16 Oct 2006	EP1948643	05 Jun 2013	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-ES-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Spain	06629821.6	16 Oct 2006	EP1948643	05 Jun 2013	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-FI-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Finland	06629821.6	16 Oct 2006	EP1948643	05 Jun 2013	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-FR-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	France	06629821.6	16 Oct 2006	EP1948643	05 Jun 2013	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-GB-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	United Kingdom	06629821.6	16 Oct 2006	EP1948643	05 Jun 2013	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-GE-NP	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Gulf Cooperation Council	GLC/P/2006/7043	10 Oct 2006	G200603811	31 Mar 2007	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	10-Oct-26
PATD34561	PATD34561-GR-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Greece	06629821.6	16 Oct 2006	20130401827	05 Jun 2013	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PATD34561	PATD34561-GT-NP	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Guatemala	PI-200800019	20 Apr 2008	5809	28 Nov 2011	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	20-Apr-28

PAT034561	PAT034561-HK-PPT	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Hong Kong	08113800.5	19 Dec 2008 1130599	11 Oct 2013	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	16 Oct-16	16-Oct-26
PAT034561	PAT034561-HR-EPT	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Croatia	06828821.6	16 Oct 2006 EP1948643	05 Jun 2013	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	16 Oct-16	16-Oct-26
PAT034561	PAT034561-HU-EPT	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Hungary	08828821.6	16 Oct 2006 EP1948643	05 Jun 2013	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	16 Oct-16	16-Oct-26
PAT034561	PAT034561-ID-PCT	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Indonesia	W00200605202	16 Oct 2006 EP1948643	20 Nov 2014	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	20-Nov-16	16-Oct-26
PAT034561	PAT034561-IE-EPT	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Ireland	06828821.6	16 Oct 2006 EP1948643	05 Jun 2013	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	16 Oct-16	16-Oct-26
PAT034561	PAT034561-IL-PCT	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Israel	190330	16 Oct 2006 EP1948643	01 Apr 2014	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	16 Oct-16	16-Oct-26
PAT034561	PAT034561-IN-PCT	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	India	2731/DELN/08	16 Oct 2006	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	16 Oct-16	16-Oct-26	
PAT034561	PAT034561-IT-NP	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Iraq	2177/2006	16 Oct 2006 3542	28 Feb 2013	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	3-Dec-16	4-Dec-26
PAT034561	PAT034561-IS-EPT	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Iceland	06828821.6	16 Oct 2006 EP1948643	05 Jun 2013	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	16 Oct-16	16-Oct-26
PAT034561	PAT034561-JT-EPT	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Italy	06828821.6	16 Oct 2006 EP1948643	05 Jun 2013	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	16 Oct-16	16-Oct-26
PAT034561	PAT034561-JO-NP	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Jordan	369/2006	16 Oct 2006 3826	17 Dec 2015	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	15-Oct-16	15-Oct-26
PAT034561	PAT034561-JP-PCT	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Japan	2008-535948	16 Oct 2006 3356931	06 Sep 2013	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	6-Sep-16	16-Oct-26
PAT034561	PAT034561-JP-PCTD	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Japan	2012-213001	26 Sep 2012 5792139	14 Aug 2015	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	14-Aug-18	16-Oct-26
PAT034561	PAT034561-KR-PCT	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	South Korea / Republic of Korea	2008-7009098	16 Oct 2006 3294432	01 Aug 2013	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	1 Aug-16	16-Oct-26
PAT034561	PAT034561-LB-NP	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Lebanon	7673	13 Oct 2006 7673	29 Dec 2006	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	13-Oct-16	13-Oct-26
PAT034561	PAT034561-LT-EPT	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Lithuania	06828821.6	16 Oct 2006 EP1948643	05 Jun 2013	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	16 Oct-16	16-Oct-26
PAT034561	PAT034561-LU-EPT	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Luxembourg	06828821.6	16 Oct 2006 EP1948643	05 Jun 2013	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	16 Oct-16	16-Oct-26
PAT034561	PAT034561-LV-EPT	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Latvia	06828821.6	16 Oct 2006 EP1948643	05 Jun 2013	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	16 Oct-16	16-Oct-26
PAT034561	PAT034561-MA-PCT	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Morocco	PA30796	16 Oct 2006 35795	01 Dec 2014	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	16 Oct-16	16-Oct-26
PAT034561	PAT034561-MC-EPT	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Monaco	06828821.6	16 Oct 2006 EP1948643	05 Jun 2013	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	16 Oct-16	16-Oct-26
PAT034561	PAT034561-MT-NP	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Malta	3823	16 Oct 2006 3823	23 Nov 2017	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	16 Oct-16	16-Oct-26
PAT034561	PAT034561-MX-PCT	3-Alkyl-5-(4-alkyl-5-oxo-1,2,4-triazol-2-yl)pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Reelin Inhibitors	Organic Compounds	Mexico	MX/A/08/004920	16 Oct 2006 303852	28 Sep 2012	Novartis AG	United Kingdom (UK) - Grant 17 Oct 2005 - 0521083.6	16 Oct-17	16-Oct-26

PAT034561	PAT034561-MV-PCT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Malaysia	PI200611108	16 Oct 2006 MY-145466-A	15 Feb 2013	Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Grant	15 Feb-17	16-Oct-26
PAT034561	PAT034561-NL-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Netherlands	06628821.6	16 Oct 2006 EP1948643	05 Jun 2013	Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Grant	31-Oct-16	16-Oct-28
PAT034561	PAT034561-MO-PCT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Norway	20080263	16 Oct 2006		Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Local filing	31-Oct-16	16-Oct-26
PAT034561	PAT034561-NZ-PCT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	New Zealand	567042	16 Oct 2006 567042	05 Jun 2012	Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Grant	16-Oct-16	16-Oct-26
PAT034561	PAT034561-PE-DIV	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Peru	3455/2011-DIV	09 Aug 2011 7347	09 Dec 2014	Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Grant	31-Oct-16	16-Oct-26
PAT034561	PAT034561-PE-NP	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Peru	001252/2006-0104	16 Oct 2006		Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Publication of Application	31-Oct-16	16-Oct-26
PAT034561	PAT034561-PL-PCT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Philippines	1-2009-500870	16 Oct 2006 1-2009-500870	31 Jul 2013	Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Publication of grant	26-Aug-17	16-Oct-26
PAT034561	PAT034561-PK-NP	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Pakistan	1382/2006	16 Oct 2006		Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Filed	17-Oct-2015 - 0521083.6	17-Oct-25
PAT034561	PAT034561-PL-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Poland	06828821.6	16 Oct 2006 EP1948643	05 Jun 2013	Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Grant	16-Oct-16	16-Oct-26
PAT034561	PAT034561-PT-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Portugal	06828821.6	16 Oct 2006 EP1948643	05 Jun 2013	Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Grant	16-Oct-16	16-Oct-26
PAT034561	PAT034561-RO-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Romania	06828821.6	16 Oct 2006 EP1948643	05 Jun 2013	Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Grant	16-Oct-16	16-Oct-26
PAT034561	PAT034561-RU-PCT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Russian Federation	2008119276	16 Oct 2006 7432354	27 Oct 2013	Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Grant	16-Oct-16	16-Oct-26
PAT034561	PAT034561-SE-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Sweden	06828821.6	16 Oct 2006 EP1948643	05 Jun 2013	Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Grant	16-Oct-16	16-Oct-26
PAT034561	PAT034561-SG-PCTD	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Singapore	201001457.3	12 Oct 2010 166153	05 Jun 2013	Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Grant	31-Oct-18	16-Oct-26
PAT034561	PAT034561-SI-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Slovenia	06828821.6	16 Oct 2006 P200631641	05 Jun 2013	Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Grant	16-Oct-16	16-Oct-26
PAT034561	PAT034561-SK-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Slovakia	06828821.6	16 Oct 2006 EP1948643	05 Jun 2013	Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Grant	16-Oct-16	16-Oct-26
PAT034561	PAT034561-TH-NP	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Thailand	060400504.2	12 Oct 2006		Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Local filing	31-Oct-18	16-Oct-26
PAT034561	PAT034561-TW-PCT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Tunisia	SH08170	16 Oct 2006		Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Publication of Application	16-Oct-18	12-Oct-26
PAT034561	PAT034561-TR-EPT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Turkey	06828821.6	16 Oct 2006		Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Local filing	31-Oct-18	16-Oct-26
PAT034561	PAT034561-TW-NP	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	Taiwan	095138055	16 Oct 2006 1995723	05 Jun 2013	Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Publication of grant	16-Oct-16	16-Oct-26
PAT034561	PAT034561-US-PCT	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	United States of America	12/088457	16 Oct 2006 7772405	10 Aug 2010	Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Grant	10-Feb-18	17-Oct-28
PAT034561	PAT034561-US-PCTD	3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)-pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors Organic Compounds	United States of America	13/823699	25 Jun 2010 8196465	12 Jun 2012	Novartis AG	17 Oct 2005 - 0521083.6	United Kingdom (NP) - Grant	12-Dec-19	19-Jan-27

PAT034361	PAT034561-VE-NP	3-alkyl-5-(4-alkyl-5-oxo-1H-pyrrolidin-2-yl)pentan-1-one Derivatives as Intermediates in the Synthesis of Benzil Inhibitors	Venezuela	2356-06	17 Oct 2006	Novartis AG	United Kingdom (NP) - Filed 17 Oct 2005 - 0621083.6	17-Oct-26
PAT034561	PAT034561-ZA-PCT	3-Alkyl-5-(4-alkyl-5-oxo-1H-pyrrolidin-2-yl)pentan-1-one Derivatives as Intermediates in the Synthesis of Benzil Inhibitors	South Africa	2008/03632	16 Oct 2006 2008/02632	Novartis AG	United Kingdom (NP) - Grant 17 Oct 2005 - 0521083.6	16-Oct-26
PAT030269	PAT030269-US-PCT	one Derivatives as Intermediates in the Synthesis of Renin Inhibitors	United States of America	12/204284	21 Jun 2007 8618172	Novartis AG	United Kingdom (NP) - Grant 0612548.5 23 Jun 2006 -	6-Oct-26
PAT030866	PAT030866-US-PCT	Galactical Formulations of Organic Compounds	United States of America	13/063955	22 Sep 2008 8613849	Novartis AG	United States of America (PSP) - 22 Sep 2008 - 13/063955	21-Elec-29
PAT030222	PAT030222-AR-NP	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 3 intermediates	Argentina	P030103194	04 Jul 2001 8402956481	Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329700	4-Jul-16
PAT030222	PAT030222-AT-EPT	SEP 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 3 intermediates	Austria	01940047.2	26 Jun 2001 1296935	Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329700	26-Jun-21
PAT030222	PAT030222-AU-PCT	SEP 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 3 intermediates	Australia	2001123763	26 Jun 2001 2001123763	Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329700	26-Jun-21
PAT030222	PAT030222-BE-EPT	SEP 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 3 intermediates	Belgium	01940047.2	26 Jun 2001 1296935	Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329700	26-Jun-21
PAT030222	PAT030222-BR-PCT	SEP 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 3 intermediates	Brazil	PI0112362.9	26 Jun 2001 PI0112362.9	Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329700	31-Oct-23
PAT030222	PAT030222-CH-EPT	SEP 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 3 intermediates	Switzerland	01940047.2	25 Jun 2001 1296935	Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329700	26-Jun-21
PAT030222	PAT030222-CN-PCT	SEP 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 3 intermediates	China	01812381.7	26 Jun 2001	Novartis AG	Switzerland (NP) - 05 Allowed Jul 2000 - 1329700	26-Jun-21
PAT030222	PAT030222-CN-PCTO	SEP 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 3 intermediates	China	200510108857.6	26 Jun 2001 200510108857.6	Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329700	26-Jun-21
PAT030222	PAT030222-CY-EPT	SEP 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 3 intermediates	Cyprus (Republic)	01940047.2	26 Jun 2001 C069/1100571	Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329700	26-Jun-21

PAT053022	PAT053022-DE-EPT					Germany	01940047.2	26 Jun 2001 1296935	25 Mar 2009 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	30-Jun-17	26-Jun-21
		a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylester b) 3 intermediates										
PAT053022	PAT053022-DK-EPT					Denmark	01940047.2	26 Jun 2001 1296935	25 Mar 2009 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	30-Jun-17	26-Jun-21
		Spp 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylester b) 3 intermediates										
PAT053022	PAT053022-EP-EPT					European Procedure	01940047.2	26 Jun 2001 1296935	25 Mar 2009 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	30-Jun-17	26-Jun-21
		a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylester b) 3 intermediates										
PAT053022	PAT053022-ES-EPT					Spain	01940047.2	26 Jun 2001 1296935	25 Mar 2009 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	30-Jun-17	26-Jun-21
		Spp 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylester b) 3 intermediates										
PAT053022	PAT053022-FI-EPT					Finland	01940047.2	26 Jun 2001 1296935	25 Mar 2009 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	30-Jun-17	26-Jun-21
		Spp 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylester b) 3 intermediates										
PAT053022	PAT053022-FR-EPT					France	01940047.2	26 Jun 2001 1296935	25 Mar 2009 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	30-Jun-17	26-Jun-21
		a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylester b) 3 intermediates										
PAT053022	PAT053022-GB-EPT					United Kingdom	01940047.2	26 Jun 2001 1296935	25 Mar 2009 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	30-Jun-17	26-Jun-21
		a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylester b) 3 intermediates										
PAT053022	PAT053022-GR-EPT					Greece	01940047.2	26 Jun 2001 20990401319	25 Mar 2009 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	30-Jun-17	26-Jun-21
		Spp 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylester b) 3 intermediates										
PAT053022	PAT053022-HK-EPR					Hong Kong	06113653.2	16 Dec 2006 1093201	18 Dec 2009 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	26-Jun-17	26-Jun-21
		a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylester b) 3 intermediates										
PAT053022	PAT053022-HU-PCT					Hungary	P0201463	26 Jun 2001 220526	08 Mar 2013 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	26-Jun-17	26-Jun-21
		Spp 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylester b) 3 intermediates										
PAT053022	PAT053022-IE-EPT					Ireland	01940047.2	26 Jun 2001 1296935	25 Mar 2009 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	30-Jun-17	26-Jun-21
		a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylester b) 3 intermediates										

PA1053022	PA1053022-IL-PCT	Israel	153717	25 Jun 2001 153717	04 Feb 2009 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	26 Jun-21
PA1053022	PA1053022-IL-PCT	Israel	187795	29 Nov 2007 187795	05 Aug 2009 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	26 Jun-21
PA1053022	PA1053022-IL-PCT	Israel	187796	28 Nov 2007 187796	05 Aug 2009 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	26 Jun-21
PA1053022	PA1053022-IN-PCT	India	166716/04/07/2005	30 Sep 2005 236931	27 Oct 2009 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	26 Jun-21
PA1053022	PA1053022-IT-EPT	Italy	01940047.2	30 Jun 2001 1296935	25 Mar 2009 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	26 Jun-21
PA1053022	PA1053022-JP-PCT	Japan	2002-507765	26 Jun 2001 4900755	13 Jan 2012 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	26 Jun-21
PA1053022	PA1053022-KR-PCT	South Korea / Republic of Korea	2002-7017207	26 Jun 2001 690471	27 Feb 2007 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	26 Jun-21
PA1053022	PA1053022-LU-EPT	Luxembourg	01940047.2	26 Jun 2001 1296935	25 Mar 2009 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	26 Jun-21
PA1053022	PA1053022-MX-PCT	Mexico	PA/01/02/01/2628	26 Jun 2001 239426	11 Aug 2006 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	26 Jun-21
PA1053022	PA1053022-NL-EPT	Netherlands	01940047.2	26 Jun 2001 1296935	25 Mar 2009 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	26 Jun-21
PA1053022	PA1053022-NO-PCT	Norway	20020012	26 Jun 2001 328105	07 Dec 2009 Novartis AG	Switzerland (NP) - 05 Grant Jul 2000 - 1329/00	26 Jun-21

PAT053022	PAT053022-HZ-PCT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 3 Intermediates	New Zealand	5234089	26 Jun 2001 523088	07 Oct 2004 Novartis AG	Switzerland (EP) - 05 Grant Jul 2000 - 1329/00	26-Jun-21
PAT053022	PAT053022-NI-PCT	SPP 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 3 Intermediates	Poland	P-358887	26 Jun 2001 121898	25 Apr 2012 Novartis AG	Switzerland (EP) - 05 Grant Jul 2000 - 1329/00	26-Jun-21
PAT053022	PAT053022-PT-EPT	SPP 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 3 Intermediates	Portugal	01940047.2	26 Jun 2001 1296935	25 Mar 2009 Novartis AG	Switzerland (EP) - 05 Grant Jul 2000 - 1329/00	26-Jun-21
PAT053022	PAT053022-SE-EPT	SPP 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 3 Intermediates	Sweden	01940047.2	26 Jun 2001 1296935	25 Mar 2009 Novartis AG	Switzerland (EP) - 05 Grant Jul 2000 - 1329/00	26-Jun-21
PAT053022	PAT053022-SG-PCT	SPP 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 3 Intermediates	Singapore	200207728.7	26 Jun 2001 93985	29 Dec 2006 Novartis AG	Switzerland (EP) - 05 Grant Jul 2000 - 1329/00	26-Jun-21
PAT053022	PAT053022-TR-EPT	SPP 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 3 Intermediates	Turkey	01940047.2	26 Jun 2001 1296935	25 Mar 2009 Novartis AG	Switzerland (EP) - 05 Grant Jul 2000 - 1329/00	26-Jun-21
PAT053022	PAT053022-TW-MP	SPP 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 3 Intermediates	Taiwan	90115929	29 Jun 2001 1289551	11 Nov 2007 Novartis AG	Switzerland (EP) - 05 Grant Jul 2000 - 1329/00	29-Jun-21
PAT053022	PAT053022-US-PCT	SPP 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 3 Intermediates	United States of America	10/312987	26 Jun 2001 6729798	04 May 2004 Novartis AG	Switzerland (EP) - 05 Grant Jul 2000 - 1329/00	26-Jun-21
PAT053022	PAT053022-ZA-PCT	SPP 100 a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 3 Intermediates	South Africa	2803/00018	26 Jun 2001 2803/00018	26 May 2004 Novartis AG	Switzerland (EP) - 05 Grant Jul 2000 - 1329/00	26-Jun-21

List of patent cases in the patent families mentioned by Noden - all abandoned by Novartis

Family Number	Case reference	Internal Title	Country (Wordings)	Filing Number	Grant Number	Crit. Grant	Critical Name (Wordings)	Current Status (W/ir)
PAT053025	PAT053025-EP-EPA	Organocatalytic Nucleo- Michael addition and Henry reaction to obtain hetero bicyclic ketone precursors for SPP100	European Procedure	07105572.7			Novartis AG	Abandoned
PAT053026	PAT053026-WO-PCI	New Heptads	International Procedure Switzerland	01. Apr. 2008			Novartis AG	Close
PAT053026	PAT053026-CY-EP	Formulation Tenside - Renin-Inhibitors	European Procedure	28 Jun 2002				Abandoned
PAT053026	PAT053026-WO-PCI	SPP 100 Formulation Tenside - Renin-Inhibitors	International Procedure	25 Jun 2003				Abandoned
PAT053026	PAT053026-EP-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	European Procedure	25 Jun 2003	1317682	03 Nov 2008		Expiry of time limit for EP Opposition (EPO Form 2057) Abandon requested (Patents)
PAT053026	PAT053026-JP-PCI	SPP 100 Formulation Tenside - Renin-Inhibitors	Japan	25 Jun 2003	4519840	28 May 2010		
PAT053026	PAT053026-US-PCI	SPP 100 Formulation Tenside - Renin-Inhibitors	United States of America	25 Jun 2003				Abandoned
PAT053026	PAT053026-AU-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Austria	03761592.9	1517682	02 Nov 2006		Abandoned
PAT053026	PAT053026-DE-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Belgium	03761592.9	1517682	02 Nov 2006		Abandon requested (Patents)
PAT053026	PAT053026-CY-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Bulgaria	03761592.9	1517682	07 Nov 2006		Abandoned
PAT053026	PAT053026-CZ-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Cyprus (Republic)	03761592.9	1517682	02 Nov 2006		Abandoned
PAT053026	PAT053026-DK-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Czech Republic	03761592.9	1517682	02 Nov 2006		Abandon requested (Patents)
PAT053026	PAT053026-FE-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Denmark	03761592.9	1517682	02 Nov 2006		Abandoned
PAT053026	PAT053026-FI-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Estonia	03761592.9	1517682	02 Nov 2006		Abandon requested (Patents)
PAT053026	PAT053026-FR-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Finland	03761592.9	1517682	02 Nov 2006		Abandoned
PAT053026	PAT053026-GR-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	France	03761592.9	1517682	02 Nov 2006		Abandon requested (Patents)
PAT053026	PAT053026-HU-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Germany	03761592.9	1517682	02 Nov 2006		Abandoned
PAT053026	PAT053026-IE-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Greece	03761592.9	1517682	02 Nov 2006		Abandoned
PAT053026	PAT053026-IT-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Hungary	03761592.9	1517682	13 Feb 2007		Abandoned
PAT053026	PAT053026-LU-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Ireland	03761592.9	1517682	02 Nov 2006		Abandon requested (Patents)
PAT053026	PAT053026-MC-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Italy	03761592.9	1517682	02 Nov 2006		Abandoned
PAT053026	PAT053026-NL-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Luxembourg	03761592.9	1517682	02 Nov 2006		Abandoned
PAT053026	PAT053026-PT-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Monaco	03761592.9	1517682	02 Nov 2006		Abandon requested (Patents)
PAT053026	PAT053026-RO-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Netherlands	03761592.9	1517682	02 Nov 2006		Abandon requested (Patents)
PAT053026	PAT053026-SK-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Portugal	03761592.9	1517682	02 Nov 2006		Abandoned
PAT053026	PAT053026-SE-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Romania	03761592.9	1517682	02 Nov 2006		Abandoned
PAT053026	PAT053026-SI-EPT	SPP 100 Formulation Tenside - Renin-Inhibitors	Slovakia	03761592.9	1517682	02 Nov 2006		Abandoned

PAT053026	PAT053026-SI-EPT	Formulation: Tenside - Renin-inhibitors	Slovenia	03761592.9	25 Jun 2003 1517692	02 Nov 2006	Abandoned
PAT053026	PAT053026-ES-EPT	Formulation: Tenside - Renin-inhibitors	Spain	03761592.9	25 Jun 2003 1517692	02 Nov 2006	Abandoned
PAT053026	PAT053026-SE-EPT	Formulation: Tenside - Renin-inhibitors	Sweden	03761592.9	25 Jun 2003 1517692	02 Nov 2006	Abandoned
PAT053026	PAT053026-CH-EPT	Formulation: Tenside - Renin-inhibitors	Switzerland	03761592.9	25 Jun 2003 1517692	02 Nov 2006	Abandoned
PAT053026	PAT053026-TR-EPT	Formulation: Tenside - Renin-inhibitors	Turkey	03761592.9	25 Jun 2003 1517692	02 Nov 2006	Abandoned
PAT053026	PAT053026-CB-EPT	Formulation: Tenside - Renin-inhibitors	United Kingdom	03761592.9	25 Jun 2003 1517692	02 Nov 2006	Abandoned
PAT053018	PAT053018-CH-HP	Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4 intermediates	Switzerland	1401.99	28 Jul 1999		Special Pharma AG
PAT053018	PAT053018-CH-MP2	Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4 intermediates	Switzerland	44/00	11 Jun 2000		Special Pharma AG
PAT053018	PAT053018-AR-HP	Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4 intermediates	Argentina	P010100322	26 Jan 2001 18029793181	31 Aug 2010	Special Pharma AG
PAT053018	PAT053018-TW-HP	Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4 intermediates	Taiwan	90101507	20 Jan 2001 16105477	13 Jan 2004	Special Pharma AG
PAT053018	PAT053018-WO-PCT	Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4 intermediates	International Procedure	PCT/TC2000/000384	13 Jul 2000		Special Pharma AG
PAT053018	PAT053018-EP-EPT	Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4 intermediates	European Procedure	00940108.4	13 Jul 2000 1200390	27 Aug 2008	Special Pharma AG
PAT053018	PAT053018-JP-PCT	Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4 intermediates	Japan	2001-544287	13 Jul 2000 4952521	10 Feb 2012	Special Pharma AG
PAT053018	PAT053018-US-PCT	Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4 intermediates	United States of America	107948129	13 Jul 2000 7006079	07 Mar 2006	Special Pharma AG
PAT053018	PAT053018-US-DIV	Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4 intermediates	United States of America	11754749	21 Oct 2005 7125866	11 Jul 2006	Special Pharma AG
PAT053018	PAT053018-AT-EPT	Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4 intermediates	Austria	00940108.4	13 Jul 2000 1200390	27 Aug 2008	Special Pharma AG
PAT053018	PAT053018-BE-EPT	Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4 intermediates	Belgium	00940108.4	13 Jul 2000 1200390	27 Aug 2008	Special Pharma AG
PAT053018	PAT053018-CY-EPT	Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4 intermediates	Cyprus (Republic)	00940108.4	13 Jul 2000 1200390	27 Aug 2008	Special Pharma AG
PAT053018	PAT053018-DK-EPT	Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4 intermediates	Denmark	00940108.4	13 Jul 2000 1200390	27 Aug 2008	Special Pharma AG
PAT053018	PAT053018-FI-EPT	Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4 intermediates	Finland	00940108.4	13 Jul 2000 1200390	27 Aug 2008	Special Pharma AG
PAT053018	PAT053018-FR-EPT	Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4 intermediates	France	00940108.4	13 Jul 2000 1200390	27 Aug 2008	Special Pharma AG
PAT053018	PAT053018-DE-EPT	Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4 intermediates	Germany	00940108.4	13 Jul 2000 1200390	27 Aug 2008	Special Pharma AG
PAT053018	PAT053018-GR-EPT	Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4 intermediates	Greece	00940108.4	13 Jul 2000 2009401195	27 Aug 2008	Special Pharma AG

PAT053018	PAT053018-1E-EPT	a) Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4-Intermediates	Ireland	00940108.4	13 Jul 2000 1200390	27 Aug 2008	Speidel Pharma AG	Abandoned
PAT053018	PAT053018-1T-EPT	SPP 100 a) Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4-Intermediates	Ialy	00940108.4	13 Jul 2000 1200390	27 Aug 2008	Speidel Pharma AG	Abandoned
PAT053018	PAT053018-1U-EPT	SPP 100 a) Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4-Intermediates	Luxembourg	00940108.4	13 Jul 2000 1200390	27 Aug 2008	Speidel Pharma AG	Abandoned
PAT053018	PAT053018-1C-EPT	SPP 100 a) Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4-Intermediates	Monaco	00940108.4	13 Jul 2000 1200390	27 Aug 2008	Speidel Pharma AG	Abandoned
PAT053018	PAT053018-1A-EPT	SPP 100 a) Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4-Intermediates	Netherlands	00940108.4	13 Jul 2000 1200390	27 Aug 2008	Speidel Pharma AG	Abandoned
PAT053018	PAT053018-1P-EPT	SPP 100 a) Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4-Intermediates	Portugal	00940108.4	13 Jul 2000 1200390	27 Aug 2008	Speidel Pharma AG	Abandoned
PAT053018	PAT053018-1S-EPT	SPP 100 a) Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4-Intermediates	Spain	00940108.4	13 Jul 2000 1200390	27 Aug 2008	Speidel Pharma AG	Abandoned
PAT053018	PAT053018-1E-EPT	SPP 100 a) Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4-Intermediates	Sweden	00940108.4	13 Jul 2000 1200390	27 Aug 2008	Speidel Pharma AG	Abandoned
PAT053018	PAT053018-1C-EPT	SPP 100 a) Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4-Intermediates	Switzerland	00940108.4	13 Jul 2000 1200390	27 Aug 2008	Speidel Pharma AG	Abandoned
PAT053018	PAT053018-1E-EPT	SPP 100 a) Process for manufacture of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryloctanoylamides b) 4-Intermediates	United Kingdom	00940108.4	13 Jul 2000 1200390	27 Aug 2008	Speidel Pharma AG	Abandoned
PAT053019	PAT053019-CN-NP	SPP 100 a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids b) Enantioselective process	Switzerland	1401/99	26 Jul 1999		Speidel Pharma AG	Abandoned
PAT053019	PAT053019-CH-NP02	SPP 100 a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids b) Enantioselective process	Switzerland	44/00	11 Jan 2000		Speidel Pharma AG	Abandoned
PAT053019	PAT053019-AG-NP	SPP 100 a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids b) Enantioselective process	Argentina	8010100391	29 Jan 2001		Speidel Pharma AG	Abandoned
PAT053019	PAT053019-TW-NP	SPP 100 a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids b) Enantioselective process	Taiwan	50101505	20 Jan 2000 1271399	21 Jan 2007	Speidel Pharma AG	Abandoned
PAT053019	PAT053019-WO-ECT	SPP 100 a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids b) Enantioselective process	International Procedure	PCT/CH2003/000385	13 Jul 2000		Speidel Pharma AG	National Phase Completion
PAT053019	PAT053019-EP-EPT	SPP 100 a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids b) Enantioselective process	European Procedure	00940109.2	13 Jul 2000 1200384	28 Apr 2004	Speidel Pharma AG	Grant
PAT053019	PAT053019-JP-EPT	SPP 100 a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids b) Enantioselective process	Japan	2001-514283	13 Jul 2000 1586006	03 Sep 2010	Speidel Pharma AG	Abandoned
PAT053019	PAT053019-US-PCT	SPP 100 a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids b) Enantioselective process	United States w/ Atlanta	10/046390	13 Jul 2000 677574	17 Aug 2004	Speidel Pharma AG	Abandoned
PAT053019	PAT053019-AT-EPT	SPP 100 a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids b) Enantioselective process	Austria	00940109.2	13 Jul 2000 1200384	28 Apr 2004	Speidel Pharma AG	Abandoned
PAT053019	PAT053019-BE-EPT	SPP 100 a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids b) Enantioselective process	Belgium	00940109.2	13 Jul 2000 1200384	28 Apr 2004	Speidel Pharma AG	Abandoned
PAT053019	PAT053019-CY-EPT	SPP 100 a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids b) Enantioselective process	Cyprus (Republic)	00940109.2	13 Jul 2000 1200384	28 Apr 2004	Speidel Pharma AG	Abandoned
PAT053019	PAT053019-DK-EPT	SPP 100 a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids b) Enantioselective process	Denmark	00940109.2	13 Jul 2000 1200384	28 Apr 2004	Speidel Pharma AG	Abandoned
PAT053019	PAT053019-FI-EPT	SPP 100 a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids b) Enantioselective process	Finland	00940109.2	13 Jul 2000 1200384	28 Apr 2004	Speidel Pharma AG	Abandoned
PAT053019	PAT053019-FR-EPT	SPP 100 a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids b) Enantioselective process	France	00940109.2	13 Jul 2000 1200384	28 Apr 2004	Speidel Pharma AG	Abandoned
PAT053019	PAT053019-DE-EPT	SPP 100 a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids b) Enantioselective process	Germany	00940109.2	13 Jul 2000 90005271.4	28 Apr 2004	Speidel Pharma AG	Abandoned

PAT053019	GR-EPT	a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids SPP 100 b) Enantioselective process	Greece	00940109.2	13 Jul 2000 1200384	26 Apr 2004	Speidel Pharma AG	Abandoned
PAT053019	IE-EPT	a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids SPP 100 b) Enantioselective process	Ireland	00940109.2	13 Jul 2000 1200384	30 Apr 2004	Speidel Pharma AG	Abandoned
PAT053019	IT-EPT	a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids SPP 100 b) Enantioselective process	Italy	00940109.2	13 Jul 2000 1200384	29 Apr 2004	Speidel Pharma AG	Abandoned
PAT053019	LU-EPT	a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids SPP 100 b) Enantioselective process	Luxembourg	00940109.2	13 Jul 2000 1200384	28 Apr 2004	Speidel Pharma AG	Abandoned
PAT053019	MC-EPT	a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids SPP 100 b) Enantioselective process	Monaco	00940109.2	13 Jul 2000 1200384	28 Apr 2004	Speidel Pharma AG	Abandoned
PAT053019	NL-EPT	a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids SPP 100 b) Enantioselective process	Netherlands	00940109.2	13 Jul 2000 1200384	28 Apr 2004	Speidel Pharma AG	Abandoned
PAT053019	PT-EPT	a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids SPP 100 b) Enantioselective process	Portugal	00940109.2	13 Jul 2000 1200384	28 Apr 2004	Speidel Pharma AG	Abandoned
PAT053019	ES-EPT	a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids SPP 100 b) Enantioselective process	Spain	00940109.2	13 Jul 2000 1200384	28 Apr 2004	Speidel Pharma AG	Abandoned
PAT053019	SE-EPT	a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids SPP 100 b) Enantioselective process	Sweden	00940109.2	13 Jul 2000 1200384	28 Apr 2004	Speidel Pharma AG	Abandoned
PAT053019	CH-EPT	a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids SPP 100 b) Enantioselective process	Switzerland	00940109.2	13 Jul 2000 1200384	28 Apr 2004	Speidel Pharma AG	Abandoned
PAT053019	GB-EPT	a) 2-alkyl-5-halogen-pent-4-ene carboxylic acids SPP 100 b) Enantioselective process	United Kingdom	00940109.2	13 Jul 2000 1200384	28 Apr 2004	Speidel Pharma AG	Abandoned
PAT053023	CH-IP	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Switzerland	1464/00	25 Jul 2000			Abandoned
PAT053023	AR-IP	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Argentina	P0101034.90	26 Jul 2001 1402587901	30 Sep 2010	Speidel Pharma AG	Abandoned
PAT053023	TW-IP	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Taiwan	90115728	26 Jun 2001 1222424	21 Oct 2004	Speidel Pharma AG	Abandoned
PAT053023	WO-PCT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	International Procedure	PCT/CH2001/000400	26 Jun 2001			National Phase Completion
PAT053023	CA-PCT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Canada	2412452	26 Jun 2001 2412452	30 Dec 2008	Speidel Pharma AG	Abandoned
PAT053023	EP-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	European Procedure	01940048.0	26 Jun 2001 1200384	26 May 2004		Expiry of time limit for EP Opposition (EPO Form 2057)
PAT053023	JP-PCT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Japan	2002-514081	16 Jun 2001 4853868	04 Nov 2011	Speidel Pharma AG	Abandoned
PAT053023	US-PCT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	United States of America	10/333947	26 Jun 2001 6800769	08 Oct 2004	Speidel Pharma AG	Abandoned
PAT053023	AT-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Austria	01940048.0	26 Jun 2001 1302478	26 May 2004	Speidel Pharma AG	Abandoned
PAT053023	BE-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Belgium	01940048.0	26 Jun 2001 1301378	26 May 2004	Speidel Pharma AG	Abandoned

PAT053023	PAT053023-CH-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates SPP 100	Cyprus (Republic)	01940048.0	26 Jun 2001 1303478	26 May 2004 Special Pharma AG	Abandoned
PAT053023	PAT053023-DK-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates SPP 100	Denmark	01940048.0	26 Jun 2001 1303478	26 May 2004 Special Pharma AG	Abandoned
PAT053023	PAT053023-FI-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates SPP 100	Finland	01940048.0	26 Jun 2001 1303478	26 May 2004 Special Pharma AG	Abandoned
PAT053023	PAT053023-FR-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates SPP 100	France	01940048.0	26 Jun 2001 1303478	26 May 2004 Special Pharma AG	Abandoned
PAT053023	PAT053023-DE-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates SPP 100	Germany	01940048.0	26 Jun 2001 1303478	26 May 2004 Special Pharma AG	Abandoned
PAT053023	PAT053023-GR-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates SPP 100	Greece	01940048.0	26 Jun 2001 1303478	26 May 2004 Special Pharma AG	Abandoned
PAT053023	PAT053023-IE-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates SPP 100	Ireland	01940048.0	26 Jun 2001 1303478	26 May 2004 Special Pharma AG	Abandoned
PAT053023	PAT053023-IT-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates SPP 100	Italy	01940048.0	26 Jun 2001 1303478	26 May 2004 Special Pharma AG	Abandoned
PAT053023	PAT053023-NL-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates SPP 100	Netherlands	01940048.0	26 Jun 2001 1303478	26 May 2004 Special Pharma AG	Abandoned
PAT053023	PAT053023-PT-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates SPP 100	Portugal	01940048.0	26 Jun 2001 1303478	26 May 2004 Special Pharma AG	Abandoned
PAT053023	PAT053023-ES-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates SPP 100	Spain	01940048.0	26 Jun 2001 1303478	26 May 2004 Special Pharma AG	Abandoned
PAT053023	PAT053023-SE-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates SPP 100	Sweden	01940048.0	26 Jun 2001 1303478	26 May 2004 Special Pharma AG	Abandoned
PAT053023	PAT053023-CH-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates SPP 100	Switzerland	01940048.0	26 Jun 2001 1303478	26 May 2004 Special Pharma AG	Abandoned
PAT053023	PAT053023-TR-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates SPP 100	Turkey	01940048.0	26 Jun 2001 1303478	26 May 2004 Special Pharma AG	Abandoned
PAT053023	PAT053023-GB-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates SPP 100	United Kingdom	01940048.0	26 Jun 2001 1303478	26 May 2004 Special Pharma AG	Abandoned
PAT053023	PAT053023-AU-EPT	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates SPP 100	Austria	525872077	19 Nov 2007 873672007	18 Mar 2008 Special Pharma AG	Abandoned
PAT053023	PAT053023-BE-SPC	a) Process for manufacture of (2S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates SPP 100	Belgium	2007C/066	21 Nov 2007 2007C/066	07 Oct 2008 Special Pharma AG	Abandoned

PAT053023	PAT053023-CH-SPC	a) Process for manufacture of (2S),4(S),6(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Switzerland	CO1303479/01	01 Nov 2007	CO1303479/01	30 Jun 2009	Speedel Pharma AG	Abandoned
PAT053023	PAT053023-CY-SPC	a) Process for manufacture of (2S),4(S),6(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Cyprus (Republic)	SPC/CY/007/029	04 Dec 2007	SPC/CY/007/029	02 Jul 2009	Speedel Pharma AG	Abandoned
PAT053023	PAT053023-DE-SPC	a) Process for manufacture of (2S),4(S),6(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Germany	L22007000077_4	16 Nov 2007	L22007000077_4	25 Mar 2009	Speedel Pharma AG	Abandoned
PAT053023	PAT053023-DK-SPC	a) Process for manufacture of (2S),4(S),6(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Denmark	CA200700057	27 Nov 2007	CA200700057	19 May 2008	Speedel Pharma AG	Abandoned
PAT053023	PAT053023-ES-SPC	a) Process for manufacture of (2S),4(S),6(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Spain	SPC300800109	06 Feb 2008	SPC300800109	04 Nov 2009	Speedel Pharma AG	Abandoned
PAT053023	PAT053023-FI-SPC	a) Process for manufacture of (2S),4(S),6(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Finland	L30070027	17 Dec 2007	L30070027	02 Jun 2011	Speedel Pharma AG	Abandoned
PAT053023	PAT053023-FR-SPC	a) Process for manufacture of (2S),4(S),6(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	France	07CD070	17 Dec 2007	07CD070	07 Jan 2009	Speedel Pharma AG	Abandoned
PAT053023	PAT053023-GB-SPC	a) Process for manufacture of (2S),4(S),6(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	United Kingdom	SPC/GB/07/064	16 Nov 2007	SPC/GB/07/064	28 Oct 2008	Speedel Pharma AG	Abandoned
PAT053023	PAT053023-GR-SPC	a) Process for manufacture of (2S),4(S),6(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Greece	20070600651	27 Nov 2007	20070600651		Speedel Pharma AG	Abandoned
PAT053023	PAT053023-IE-SPC	a) Process for manufacture of (2S),4(S),6(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Ireland	2007/044	14 Nov 2007	2007/044	16 Jul 2008	Speedel Pharma AG	Abandoned
PAT053023	PAT053023-IT-SPC	a) Process for manufacture of (2S),4(S),6(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Italy	C-1032007CD1037	25 Nov 2007	C-1032007CD1037	04 Mar 2008	Speedel Pharma AG	Abandoned
PAT053023	PAT053023-NL-SPC	a) Process for manufacture of (2S),4(S),6(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Netherlands	300305	13 Nov 2007	300305	06 Dec 2007	Speedel Pharma AG	Abandoned
PAT053023	PAT053023-PT-SPC	a) Process for manufacture of (2S),4(S),6(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Portugal	5050604	18 Mar 2008	5050604	28 Oct 2008	Speedel Pharma AG	Abandoned
PAT053023	PAT053023-SE-SPC	a) Process for manufacture of (2S),4(S),6(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides b) 2 intermediates	Sweden	0790657-4	20 Nov 2007	0790657-4	19 Mar 2009	Speedel Pharma AG	Abandoned
PAT053025	PAT053025-CH-PP	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	Switzerland	895/01	15 May 2001	895/01		Abandoned	
PAT053025	PAT053025-NO-PCT	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	International Procedure	PCT/EP2002/004640	26 Apr 2002	PCT/EP2002/004640		National Phase Completion	
PAT053025	PAT053025-BR-PCT	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	Brazil	PI0309657-9	26 Apr 2002	PI0309657-9	21 Oct 2014	Speedel Pharma AG	Abandoned
PAT053025	PAT053025-CA-PCT	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	Canada	2445014	26 Apr 2002	2445014	11 Oct 2011	Speedel Pharma AG	Abandoned

PAT053025	PAT053025-CN-PCT	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	China	02809952.4	26 Apr 2002 02809952.4	11 Oct 2006 Speedel Pharma AG	Abandoned
	SPP 100						
PAT053025	PAT053025-EP-EPT	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	European Procedure	02735305.1	26 Apr 2002 1412514	17 Feb 2010	Expiry of time limit for EP Opposition (EPO Form 2007)
	SPP 100						
PAT053025	PAT053025-IN-PCT	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	India	21090DELAP72003	26 Apr 2002 247013	25 Mar 2011 Speedel Pharma AG	Abandoned
	SPP 100						
PAT053025	PAT053025-IL-PCT	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	Israel	150596	26 Apr 2002 150596	08 Nov 2008 Speedel Pharma AG	Abandoned
	SPP 100						
PAT053025	PAT053025-JP-PCT	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	Japan	2002-506994	26 Apr 2002 0322083	30 Jan 2009 Speedel Pharma AG	Abandoned
	SPP 100						
PAT053025	PAT053025-MX-PCT	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	Mexico	02710294	26 Apr 2002 249175	20 Sep 2007 Speedel Pharma AG	Abandoned
	SPP 100						
PAT053025	PAT053025-RK-PCT	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	South Korea / Republic of Korea	10-2003-701874	26 Apr 2002	Special Pharma AG	Abandoned
	SPP 100						
PAT053025	PAT053025-US-PCT	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	United States of America	10/417739	26 Apr 2002 7152675	36 Dec 2006 Special Pharma AG	Abandoned
	SPP 100						
PAT053025	PAT053025-HK-FPR	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	Hong Kong	04106218.9	15 Aug 2004	Abandoned	
	SPP 100						
PAT050853	PAT050853-DJ-PCT	New Methods	Algeria	090828	01 Apr 2008 6783	28 Jun 2011 Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-AU-PCT	New Methods	Australia	2006234834	01 Apr 2008 2006234834	03 May 2012 Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-BR-PCT	New Methods	Brazil	09080578.3	01 Apr 2008	Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-CN-PCT	New Methods	Canada	20080015233.8	01 Apr 2008	Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-CA-PCT	New Methods	Colombia	09117976	01 Apr 2008	Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-EC-PCT	New Methods	Ecuador	09-9708	01 Apr 2008	Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-EG-PCT	Organocatalytic Nitro-Michael addition and Henry reaction to obtain beta-amine precursors for SPP100	Egypt	PC71430/2009	01 Apr 2008	Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-CT-PCT	New Methods	European Procedure	8735661.4	01 Apr 2008	Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-IN-PCT	New Methods	India	01-2008-01069	01 Apr 2008	Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-ID-PCT	New Methods	Indonesia	W0020090222	01 Apr 2008	Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-IL-PCT	New Methods	Israel	201054	01 Apr 2008	Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-JP-PCT	New Methods	Japan	2011-561301	01 Apr 2008	Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-KR-PCT	New Methods	Korea	PI2009-4018	01 Apr 2008	Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-MY-PCT	New Methods	Malaysia	07/10/0101699	01 Apr 2008 11325	Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-NZ-PCT	New Methods	New Zealand	572743	01 Apr 2008 572743	09 Jul 2012 Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-PH-PCT	New Methods	Philippines	1-2009-501844	01 Apr 2008 155664	13 Apr 2012 Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-SG-PCT	New Methods	Singapore	200906378.3	01 Apr 2008 155664	13 Apr 2012 Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-ZA-PCT	New Methods	South Africa	2009/06190	01 Apr 2008 2009/06190	26 May 2010 Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-KR-PCT	New Methods	South Korea / Republic of Korea	3009-702282	01 Apr 2008	Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-TN-PCT	New Methods	Tunisia	TN/2008/0401	01 Apr 2008	Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-AR-PCT	New Methods	United Arab Emirates	PH83709	01 Apr 2008	Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-US-PCT	New Methods	United States of America	127594414	01 Apr 2008 8339620	28 Dec 2012 Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-HK-FPR	New Methods	Hong Kong	10105144.2	26 May 2010	Novartis AG	Abandoned
	SPP 100						
PAT050853	PAT050853-RU-PCT	New Methods	Russian Federation	2005140306	01 Apr 2008	Novartis AG	Abandoned
	SPP 100						
PAT053025	PAT053025-AT-EPT	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	Austria	02735305.1	26 Apr 2002 1412514	17 Feb 2010 Speedel Pharma AG	Abandoned
	SPP 100						
PAT053025	PAT053025-SE-EPT	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	Belgium	02735305.1	26 Apr 2002 1412514	17 Feb 2010 Speedel Pharma AG	Abandoned
	SPP 100						
PAT053025	PAT053025-FR-EPT	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	France	02735305.1	26 Apr 2002 1412514	17 Feb 2010 Speedel Pharma AG	Abandoned
	SPP 100						
PAT053025	PAT053025-DE-EPT	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	Germany	02735305.1	26 Apr 2002 60235374.2	17 Feb 2010 Special Pharma AG	Abandoned
	SPP 100						

PA1053025	PA1053025-GH-EPT SPP 100	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	Greece	02735305.1	26 Apr 2002 20071829	17 Feb 2010 Spezial Pharma AG	Abandoned
PA1053025	PA1053025-IT-EPT SPP 100	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	Italy	02735305.1	26 Apr 2002 234779672010	17 Feb 2010 Spezial Pharma AG	Abandoned
PA1053025	PA1053025-NL-EPT SPP 100	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	Netherlands	02735305.1	26 Apr 2002 1412314	17 Feb 2010 Spezial Pharma AG	Abandoned
PA1053025	PA1053025-PT-EPT SPP 100	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	Portugal	02735305.1	26 Apr 2002 1412314	17 Feb 2010 Spezial Pharma AG	Abandoned
PA1053025	PA1053025-CH-EPT SPP 100	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	Switzerland	02735305.1	26 Apr 2002 1412314	17 Feb 2010 Spezial Pharma AG	Abandoned
PA1053025	PA1053025-TR-EPT SPP 100	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	Turkey	02735305.1	26 Apr 2002 TR-01.003374	17 Feb 2010 Spezial Pharma AG	Abandoned
PA1053025	PA1053025-GB-EPT SPP 100	a) Process for manufacture of (2S)-alkyl-5-pent-4-ene carboxylic acids under recycling of (2R)-enantiomer	United Kingdom	02735305.1	26 Apr 2002 1412314	17 Feb 2010 Spezial Pharma AG	Abandoned